AI assistant
Sending…
Vanda Pharmaceuticals Inc. — Director's Dealing 2025
Jun 17, 2025
33390_dirs_2025-06-16_19ddf422-c483-450d-980c-b7078e02f8d9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2025-06-13
Reporting Person: Mitchell Stephen Ray (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-13 | Common Stock | S | 7000 | $4.59 | Disposed | 97082 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
More from Vanda Pharmaceuticals Inc.
Interim / Quarterly Report
2026
May 7
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Regulatory Filings
2026
Apr 22
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Feb 24
Regulatory Filings
2026
Feb 23
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19